Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kathleen Kiernan Harnden
Observed names:
K Harnden,
K.K. Harnden,
KK Harnden,
Kathleen Harnden,
Kathleen K. Harnden
Institution:
Inova Fairfax Hospital
Observed institutions:
Inova Health System,
Duke University,
Inova Fairfax Hospital,
Duke Medical Center,
Durham VA Medical Center,
Duke Cancer Institute,
University of Virginia
show all 7
ORCID:
0000-0002-8211-708X
Observed ORCID:
0000-0002-8211-708X
OpenAlex ID:
A5043562974
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
2022
·
Francois-Clement Bidard
, Virginia G. Kaklamani
, et al.
·
Journal of Clinical Oncology
·
767
PDF
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
2024
·
Komal L. Jhaveri
, Elgene Lim
, et al.
·
Journal of Clinical Oncology
·
49
PDF
Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?
2014
·
Debu Tripathy
, Kathleen Harnden
, et al.
·
BMC Medicine
·
47
PDF
Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
2023
·
Aditya Bardia
, Francois-Clement Bidard
, et al.
·
Cancer Research
·
43
Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan
2022
·
Aditya Bardia
, Kathleen Harnden
, et al.
·
The Oncologist
·
36
PDF
A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.
2021
·
Komal L. Jhaveri
, Elgene Lim
, et al.
·
Journal of Clinical Oncology
·
36
Integration of Multitargeted Polymer-Based Contrast Agents with Photoacoustic Computed Tomography: An Imaging Technique to Visualize Breast Cancer Intratumor Heterogeneity
2021
·
Lei Li
, Deepanjali Patil
, et al.
·
ACS Nano
·
35
Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
2022
·
Aditya Bardia
, Patrick Neven
, et al.
·
Cancer Research
·
17
Management of Chemotherapy-Induced Nausea and Vomiting with Trastuzumab Deruxtecan: A Case Series
2020
·
Matthew Stankowicz
, Lauren Mauro
, et al.
·
Breast Care
·
16
PDF
Routine Use of Zoledronic Acid in Early-Stage Breast Cancer
2015
·
Kathleen Harnden
, Kimberly Blackwell
·
Journal of the National Comprehensive Cancer Network
·
12
PDF
Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).
2022
·
Virginia G. Kaklamani
, Aditya Bardia
, et al.
·
Journal of Clinical Oncology
·
10
From setbacks to success: building a promising path for strain-guided cardioprotection during anthracycline treatment
2024
·
Ana Barac
, Lauren Mauro
, et al.
·
European Heart Journal
·
6
201P Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Preliminary phase II results
2023
·
L. Seneviratne
, K.K. Harnden
, et al.
·
ESMO Open
·
6
PDF
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).
2023
·
Virginia G. Kaklamani
, Francois Clement Bidard
, et al.
·
Journal of Clinical Oncology
·
5
PDF
The feasibility of same day pegfilgrastim-cbqv administration in breast cancer patients receiving myelosuppressive chemotherapy regimens at a northern Virginia cancer center.
2021
·
Maya Leiva
, Angela Pennisi
, et al.
·
Journal of Clinical Oncology
·
4
Increased Fiber Intake Decreases Premenopausal Breast Cancer Risk
2016
·
Kathleen K. Harnden
, Kimberly L. Blackwell
·
PEDIATRICS
·
4
Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results.
2024
·
Lasika C. Seneviratne
, Kathleen Kiernan Harnden
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Cardio-Oncology Program Building
2024
·
Michelle Weisfelner Bloom
, Alana M. Ferrari
, et al.
·
Cardiology Clinics
·
2
A community hospital cancer services approach to the reduction of OP-35 rule hospitalizations.
2024
·
John F. Deeken
, Erik Dvergsten
, et al.
·
Journal of Clinical Oncology
·
1
Abstract PO3-13-01: ONTARGET: Phase 3 randomized, double-blind, placebo-controlled trial evaluating crofelemer for the prophylaxis of diarrhea in adult patients with solid tumors receiving targeted therapies with or without standard chemotherapy
2024
·
Lee Schwartzberg
, Pablo Okhuysen
, et al.
·
Cancer Research
·
1
A Case of Refractory Cardiogenic Shock and Recent Breast Cancer Treated With Surgical Resection and Orthotopic Heart Transplant
2024
·
Matteo Fabbri
, Mutaz Alkalbani
, et al.
·
Journal of the American College of Cardiology
·
1
Abstract P3-09-04: Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations
2022
·
Jing Xi
, Kathleen Harnden
, et al.
·
Cancer Research
·
1
Clinical pharmacogenomic testing impacts therapy decisions and supportive medication choices in breast cancer.
2019
·
Kathleen Kiernan Harnden
, John F. Deeken
, et al.
·
Journal of Clinical Oncology
·
1
Multisite quality improvement workshops to improve adverse event monitoring and supportive care delivery in HR+, HER2– metastatic breast cancer.
2026
·
Teresa van Oort
, Maria Alvarez
, et al.
·
JCO Oncology Practice
PDF
Abstract P2-12-24: A phase I/Ib trial of the CDK4/6 antagonist ribociclib and the HDAC inhibitor belinostat in patients with metastatic triple negative breast cancer and recurrent ovarian cancer with response prediction by genomics (CHARGE)
2025
·
Talicia Savage
, John G Lamb
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
33
Citation count:
1,103
H-index:
10
I10-index:
11
Year
Topic
Type
